$INAB
IN8BIO, INC.

2022 Q1 Form 10-K Financial Statement

#000095017022004101 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.764M $7.306M $3.179M
YoY Change 236.67% 129.82% 17.39%
% of Gross Profit
Research & Development $2.381M $7.347M
YoY Change 91.24% 36.61%
% of Gross Profit
Depreciation & Amortization $16.00K $100.0K $44.00K
YoY Change -27.27% 0.0% -4.35%
% of Gross Profit
Operating Expenses $6.145M $14.65M $8.557M
YoY Change 160.05% 71.24% 68.91%
Operating Profit -$6.145M -$14.65M
YoY Change 160.05% 71.24%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.145M -$14.65M -$8.557M
YoY Change 160.05% 71.24% 66.67%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.145M -$14.65M -$8.557M
YoY Change 160.05% 71.24% 66.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33 -$1.47
Diluted Earnings Per Share -$326.9K -$780.2K -$456.3K
COMMON SHARES
Basic Shares Outstanding 18.81M 9.970M
Diluted Shares Outstanding 18.80M 9.970M

Balance Sheet

Concept 2022 Q1 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.11M $37.02M $17.99M
YoY Change 113.31% 106.89%
Cash & Equivalents $32.36M $17.99M
Short-Term Investments
Other Short-Term Assets $1.167M $1.959M $0.00
YoY Change 264.69% 683.6%
Inventory
Prepaid Expenses $150.0K
Receivables
Other Receivables
Total Short-Term Assets $33.27M $38.98M $18.14M
YoY Change 116.46% 114.84%
LONG-TERM ASSETS
Property, Plant & Equipment $240.0K $2.834M $186.0K
YoY Change -86.49% 1423.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $158.0K $409.0K $0.00
YoY Change -95.18% -84.15%
Total Long-Term Assets $3.264M $3.243M $2.766M
YoY Change -35.38% 17.25%
TOTAL ASSETS
Total Short-Term Assets $33.27M $38.98M $18.14M
Total Long-Term Assets $3.264M $3.243M $2.766M
Total Assets $36.54M $42.22M $20.91M
YoY Change 78.91% 101.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $553.0K $395.0K $620.0K
YoY Change -16.21% -36.29%
Accrued Expenses $884.0K $1.469M $1.778M
YoY Change -49.83% -17.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $325.0K $392.0K $174.0K
YoY Change -49.22% 125.29%
Total Short-Term Liabilities $2.068M $2.256M $2.572M
YoY Change -32.46% -12.29%
LONG-TERM LIABILITIES
Long-Term Debt $201.0K $269.0K $0.00
YoY Change -34.95%
Other Long-Term Liabilities $1.434M $1.515M $0.00
YoY Change 95.63%
Total Long-Term Liabilities $1.635M $1.784M $17.00K
YoY Change 56.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.068M $2.256M $2.572M
Total Long-Term Liabilities $1.635M $1.784M $17.00K
Total Liabilities $3.703M $4.040M $2.589M
YoY Change -9.77% 56.04%
SHAREHOLDERS EQUITY
Retained Earnings -$38.84M -$18.04M
YoY Change
Common Stock $2.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.84M $38.18M -$16.58M
YoY Change
Total Liabilities & Shareholders Equity $36.54M $42.22M $20.91M
YoY Change 78.91% 101.93%

Cashflow Statement

Concept 2022 Q1 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$6.145M -$14.65M -$8.557M
YoY Change 160.05% 71.24% 66.67%
Depreciation, Depletion And Amortization $16.00K $100.0K $44.00K
YoY Change -27.27% 0.0% -4.35%
Cash From Operating Activities -$4.559M -$13.51M -$3.868M
YoY Change 81.85% 89.39% 39.24%
INVESTING ACTIVITIES
Capital Expenditures -$253.0K -$309.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$253.0K -$309.0K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $33.00K $36.33M
YoY Change 7179.96%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -102.0K 32.96M 18.68M
YoY Change -76.55% 34.42% 28641.54%
NET CHANGE
Cash From Operating Activities -4.559M -13.51M -3.868M
Cash From Investing Activities -253.0K -309.0K 0.000
Cash From Financing Activities -102.0K 32.96M 18.68M
Net Change In Cash -4.914M 19.14M 14.81M
YoY Change 67.03% 10.08% -644.03%
FREE CASH FLOW
Cash From Operating Activities -$4.559M -$13.51M -$3.868M
Capital Expenditures -$253.0K -$309.0K $0.00
Free Cash Flow -$4.306M -$13.20M -$3.868M
YoY Change 71.76% 85.06% 43.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001740279
CY2020Q4 inab Deferred Tax Liabilities Right Of Use Of Asset
DeferredTaxLiabilitiesRightOfUseOfAsset
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39692
CY2021 dei Entity Registrant Name
EntityRegistrantName
IN8BIO, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5462585
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
350 5th Avenue
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 5330
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10118
CY2021 dei City Area Code
CityAreaCode
646
CY2021 dei Local Phone Number
LocalPhoneNumber
600-6438
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
INAB
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Public Float
EntityPublicFloat
61500000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18812267
CY2021 dei Auditor Name
AuditorName
CohnReznick LLP
CY2021 dei Auditor Location
AuditorLocation
Tysons, Virginia
CY2021 dei Auditor Firm
AuditorFirmId
596
CY2021Q4 us-gaap Cash
Cash
37021000
CY2020Q4 us-gaap Cash
Cash
17994000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1959000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
150000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
38980000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18144000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
97000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186000
CY2021Q4 inab Constructions In Progress Gross
ConstructionsInProgressGross
403000
CY2020Q4 inab Constructions In Progress Gross
ConstructionsInProgressGross
0
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
251000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
141000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2439000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
704000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1630000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
158000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3243000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2766000
CY2021Q4 us-gaap Assets
Assets
42223000
CY2020Q4 us-gaap Assets
Assets
20910000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
395000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
620000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1235000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1778000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
392000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
234000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
174000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2256000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2572000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1515000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
269000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1784000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17000
CY2021Q4 us-gaap Liabilities
Liabilities
4040000
CY2020Q4 us-gaap Liabilities
Liabilities
2589000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
34900000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50700000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18781242
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18781242
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3764488
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3764488
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70872000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1458000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32691000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18038000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38183000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16579000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42223000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20910000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7347000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5378000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7306000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3179000
CY2021 us-gaap Operating Expenses
OperatingExpenses
14653000
CY2020 us-gaap Operating Expenses
OperatingExpenses
8557000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-14653000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-8557000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14653000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8557000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14653000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10340000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.02
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9969733
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3419075
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9242000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
357000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8557000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16579000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2195000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14653000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38183000
CY2021 us-gaap Profit Loss
ProfitLoss
-14653000
CY2020 us-gaap Profit Loss
ProfitLoss
-8557000
CY2021 us-gaap Depreciation
Depreciation
89000
CY2020 us-gaap Depreciation
Depreciation
88000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2195000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
357000
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
103000
CY2021 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
0
CY2020 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
248000
CY2021 inab Deferred Rent
DeferredRent
0
CY2020 inab Deferred Rent
DeferredRent
17000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
537000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
0
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
162000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1876000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
159000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
48000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-319000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-160000
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-554000
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
816000
CY2021 inab Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
158000
CY2020 inab Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
0
CY2021 inab Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
-197000
CY2020 inab Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13509000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7133000
CY2021 inab Payments For Construction In Progress
PaymentsForConstructionInProgress
309000
CY2020 inab Payments For Construction In Progress
PaymentsForConstructionInProgress
0
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-309000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36327000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
499000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
25175000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
535000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2020 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
174000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
174000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19137000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17384000
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2021 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
2693000
CY2020 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1344000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32955000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18135000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24517000
CY2021 inab Exercise Of Convertible Preferred Stock Warrants
ExerciseOfConvertiblePreferredStockWarrants
0
CY2020 inab Exercise Of Convertible Preferred Stock Warrants
ExerciseOfConvertiblePreferredStockWarrants
829000
CY2021 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
94000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1693000
CY2020 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
0
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
751000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37272000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18135000
CY2021 inab Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
CY2020 inab Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
1095000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
34900000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
309000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2021 inab Right Of Use Assets Obtained In Exchange For Operating Lease
RightOfUseAssetsObtainedInExchangeForOperatingLease
969000
CY2020 inab Right Of Use Assets Obtained In Exchange For Operating Lease
RightOfUseAssetsObtainedInExchangeForOperatingLease
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2021 inab Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
1728000
CY2020 inab Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
0
CY2021Q4 us-gaap Cash
Cash
37021000
CY2020Q4 us-gaap Cash
Cash
17994000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
251000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
141000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37272000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18135000
CY2021Q4 us-gaap Cash
Cash
37000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:3.707%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the useful lives of property and equipment, deferred tax assets and liabilities and related valuation allowance, fair value of stock-based compensation, and accrued research and development costs. Management bases certain estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:3.707%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash. The Company’s cash is maintained with a high quality, accredited financial institution. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. Management deems there to be minimal credit risk associated with the Company’s cash.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
443000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
443000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
346000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
257000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
97000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186000
CY2021 us-gaap Depreciation
Depreciation
100000
CY2020 us-gaap Depreciation
Depreciation
100000
CY2021Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
77000
CY2020Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
0
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
200000
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
0
CY2021Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
126000
CY2020Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
0
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
403000
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2021Q4 inab Accrued Offering Costs
AccruedOfferingCosts
0
CY2020Q4 inab Accrued Offering Costs
AccruedOfferingCosts
876000
CY2021Q4 inab Accrued Clinical Trials
AccruedClinicalTrials
196000
CY2020Q4 inab Accrued Clinical Trials
AccruedClinicalTrials
376000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
926000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
400000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
113000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
126000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1235000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1778000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
27564260
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9993727
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
9993727
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
38000000.0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
231396
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0003
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
800000
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1247158
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.16
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1486000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1231965
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.59
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26689
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.09
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
146055
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.76
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2306379
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.51
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M26D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
983000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
503206
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.00
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
544000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1803173
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.83
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y1M28D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
439000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.41
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.67
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
200000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
100000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2195000
CY2020 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
357000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
304000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2670000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1569000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1938000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1116000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4608000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2685000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4608000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2685000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.10
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.10
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.31
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.31
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
337000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
155000
CY2021Q4 inab Deferred Tax Assets Net Operating Loss Carryforwards And Alternative Minimum Tax Credits
DeferredTaxAssetsNetOperatingLossCarryforwardsAndAlternativeMinimumTaxCredits
6803000
CY2020Q4 inab Deferred Tax Assets Net Operating Loss Carryforwards And Alternative Minimum Tax Credits
DeferredTaxAssetsNetOperatingLossCarryforwardsAndAlternativeMinimumTaxCredits
4667000
CY2021Q4 inab Lease Accounting
LeaseAccounting
791000
CY2020Q4 inab Lease Accounting
LeaseAccounting
0
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
0
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1922000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9391000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4784000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10157000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4822000
CY2021Q4 inab Deferred Tax Liabilities Right Of Use Of Asset
DeferredTaxLiabilitiesRightOfUseOfAsset
-766000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
269000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9969733
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
38000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
766000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
38000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3419075
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1783000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14653000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10340000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.02
CY2021 inab Net Operating Loss Carryovers And Carrybacks Offset Description
NetOperatingLossCarryoversAndCarrybacksOffsetDescription
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company evaluated the impact of the CARES Act. At present, the Company does not expect that the NOL carryback provision or other provisions of the CARES Act resulting in a material tax benefit to the Company
CY2021Q4 inab Federal Nol Carryforwards
FederalNolCarryforwards
20100000
CY2021Q4 inab New York State And City Nol Carryforwards
NewYorkStateAndCityNolCarryforwards
30100000
CY2021Q4 inab Net Change In The Valuation Allowance
NetChangeInTheValuationAllowance
4600000
CY2021Q4 inab Percentage Of Stock Ownership With Regards To Limitations On The Use Of Net Operating Loss Carryovers
PercentageOfStockOwnershipWithRegardsToLimitationsOnTheUseOfNetOperatingLossCarryovers
0.05
CY2021Q4 inab Cumulative Increment In Stock Ownership Basis Points
CumulativeIncrementInStockOwnershipBasisPoints
0.50
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14653000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-8557000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
478000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1749000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
30000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
490000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
392000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
502000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
234000
CY2021 inab Royalty Term
RoyaltyTerm
P10Y
CY2020Q3 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
300000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
200750
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
537000
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
86000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
280000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
460000
CY2021 us-gaap Lease Cost
LeaseCost
1363000
CY2021Q4 inab Cash Paid For Amounts Included In Finance Leases
CashPaidForAmountsIncludedInFinanceLeases
86000
CY2021Q4 inab Cash Paid For Amounts Included In Operating Leases
CashPaidForAmountsIncludedInOperatingLeases
158000
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M20D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M23D
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.102
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2021Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
435000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
405000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
252000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
311000
CY2021Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
45000
CY2021Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
717000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2231000
CY2021Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
56000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
482000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
661000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1515000

Files In Submission

Name View Source Status
0000950170-22-004101-index-headers.html Edgar Link pending
0000950170-22-004101-index.html Edgar Link pending
0000950170-22-004101.txt Edgar Link pending
0000950170-22-004101-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img237042851_0.jpg Edgar Link pending
img237042851_1.jpg Edgar Link pending
img237042851_10.jpg Edgar Link pending
img237042851_11.jpg Edgar Link pending
img237042851_12.jpg Edgar Link pending
img237042851_13.jpg Edgar Link pending
img237042851_14.jpg Edgar Link pending
img237042851_15.jpg Edgar Link pending
img237042851_16.jpg Edgar Link pending
img237042851_17.jpg Edgar Link pending
img237042851_18.jpg Edgar Link pending
img237042851_19.jpg Edgar Link pending
img237042851_2.jpg Edgar Link pending
img237042851_20.jpg Edgar Link pending
img237042851_21.jpg Edgar Link pending
img237042851_22.jpg Edgar Link pending
img237042851_23.jpg Edgar Link pending
img237042851_24.jpg Edgar Link pending
img237042851_3.jpg Edgar Link pending
img237042851_4.jpg Edgar Link pending
img237042851_5.jpg Edgar Link pending
img237042851_6.jpg Edgar Link pending
img237042851_7.jpg Edgar Link pending
img237042851_8.jpg Edgar Link pending
img237042851_9.jpg Edgar Link pending
img46661537_0.jpg Edgar Link pending
img66978999_0.jpg Edgar Link pending
inab-20211231.htm Edgar Link pending
inab-20211231.xsd Edgar Link pending
inab-20211231_cal.xml Edgar Link unprocessable
inab-20211231_def.xml Edgar Link unprocessable
inab-20211231_htm.xml Edgar Link completed
inab-20211231_lab.xml Edgar Link unprocessable
inab-20211231_pre.xml Edgar Link unprocessable
inab-ex10_19.htm Edgar Link pending
inab-ex10_20.htm Edgar Link pending
inab-ex23_1.htm Edgar Link pending
inab-ex31_1.htm Edgar Link pending
inab-ex31_2.htm Edgar Link pending
inab-ex32_1.htm Edgar Link pending
inab-ex4_3.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending